Free tool · no sign-up
GLP-1 titration schedule planner
Map a documented GLP-1 plan to dates, concentrations, volumes, and syringe units with transparent arithmetic, without guessing or generating doses for research.
Read it from the vial — do not assume
| Step | When | Amount | Volume | Reads |
|---|
A 5 mg vial made to a final volume of 2 mL contains 2.5 mg/mL. If the documented treatment plan specifies 0.5 mg, the arithmetic gives 0.2 mL, or 20 units on a U-100 syringe. Change the final volume to 1 mL and the same 0.5 mg becomes 0.1 mL, or 10 units. The prescribed mass did not change; the concentration did.
That distinction is the central purpose of a GLP-1 titration schedule planner. A schedule can produce two very different things: a clinical instruction, or a neat-looking list of dates and measurements. Only a licensed prescriber can produce the first. A planner produces the second, then converts each documented amount into the syringe reading implied by the vial concentration.
“10 units” is not a peptide dose by itself. It is a volume marking on a particular syringe. The amount of peptide in those 10 units depends on the concentration created by the vial and the final liquid volume. Change the reconstitution volume, and the syringe reading changes even if the prescribed milligram amount does not.
What a GLP-1 titration schedule planner actually does
A GLP-1 titration schedule planner takes an existing treatment instruction and lays it out as a dated sequence. The useful inputs are the documented starting amount, the next amount or increment, the interval between planned steps, the date of the first administration, and the concentration of the preparation in hand.
The output is a calendar and a unit conversion. It can show when each planned step falls and how much liquid corresponds to that step. It cannot determine whether escalation should occur, interpret symptoms, select a compound, or correct a missed dose. Those decisions belong to the licensed prescriber managing the treatment.
A reliable planner should keep four fields separate:
- Planned amount: the mass written in the treatment instructions.
- Calculated volume: the liquid volume obtained from the concentration calculation.
- Syringe marking: the reading for the specific syringe calibration.
- Actual administration: what was used and when it was actually used.
Combining these into one field makes a later error difficult to find. A unit entry without its concentration is incomplete, because 20 units from one vial can contain a different mass from 20 units from another vial.
Dosyne is built around that narrow job. Its dose and vial records give the arithmetic a place to live alongside the date, injection site, and actual administration record. A tidy calendar is useful; a tidy calendar that disagrees with what was actually taken is tidy fiction.
Why titration exists
GLP-1 receptor activity can appear before the gastrointestinal tract has adapted to the exposure. Nausea, early fullness, vomiting, diarrhea, constipation, and reduced intake may become limiting even when the intended receptor effect is still developing. The gut does not consult the calendar.
Titration separates those two timelines. A licensed prescriber may use smaller changes or longer intervals to allow tolerance to catch up with pharmacologic exposure. The schedule is therefore not a race toward a target amount. It is a controlled way to observe what happens at one exposure before deciding whether a change is justified.
Semaglutide is generally discussed as a GLP-1 receptor agonist, while tirzepatide acts at GLP-1 and GIP receptors. That mechanistic distinction does not create a universal schedule for either compound. Formulation, indication, other medicines, medical history, and the person’s response all affect the clinical plan.
A hold means the current amount remains in place instead of moving to the next planned step. The treatment team may extend an interval because gastrointestinal symptoms remain troublesome, oral intake is inadequate, hydration is affected, or the current amount is already appropriate for the plan. A step back can also be intentional. In a record, a hold or step-back should appear as an actual dated event, not as a mysterious gap.
Mechanism is not the same as evidence. Semaglutide and tirzepatide have established clinical development programs in their approved uses, but that fact does not transfer automatically to every compounded preparation, research peptide, indication, or concentration. For compounds such as retatrutide and BPC-157, human evidence, regulatory status, formulation quality, and long-term safety questions differ substantially. A calculator cannot fill those evidence gaps.
The arithmetic: concentration first
The essential calculation has two stages. First find concentration. Then find the volume required for the documented amount.
Concentration = total peptide amount ÷ final liquid volume
Injection volume = prescribed peptide amount ÷ concentration
Keep units consistent. If the vial contains 5 mg and the final volume is 2 mL:
5 mg ÷ 2 mL = 2.5 mg/mL
If the documented amount is 0.5 mg:
0.5 mg ÷ 2.5 mg/mL = 0.2 mL
A U-100 insulin syringe contains 100 units per milliliter, so:
0.2 mL × 100 units/mL = 20 units
The resulting syringe reading is 20 U on a U-100 syringe. It is not 20 mg, 20 micrograms, or a universal measure across syringe types.
For a more detailed worked calculation, see the Peptide reconstitution calculator that shows its working. The point of showing the working is error detection. A result without the concentration and volume steps hides the places where a decimal, unit, or vial assumption went wrong.
Milligrams, micrograms, milliliters, and units
The common mass conversion is:
1 mg = 1,000 mcg
Thus, 250 mcg equals 0.25 mg. Do not convert milligrams directly to syringe units without first knowing the final concentration and the syringe scale. “Units” describes volume on a calibrated syringe; it does not describe peptide mass.
The general formula for a U-100 syringe is:
Syringe units = prescribed amount ÷ concentration × 100
If concentration is expressed in mg/mL, the prescribed amount must also be in mg. If concentration is expressed in mcg/mL, the prescribed amount must also be in mcg. Mixing mg and mcg creates a 1,000-fold error, which can turn a correct-looking calculation into a dangerous one.
| Quantity | Formula | Example |
|---|---|---|
| Concentration | vial amount ÷ final volume | 5 mg ÷ 2 mL = 2.5 mg/mL |
| Injection volume | prescribed amount ÷ concentration | 0.5 mg ÷ 2.5 mg/mL = 0.2 mL |
| U-100 syringe reading | volume × 100 | 0.2 mL × 100 = 20 U |
| Mass from volume | volume × concentration | 0.1 mL × 2.5 mg/mL = 0.25 mg |
A U-100 syringe is not the only possible scale. Confirm the marking printed on the syringe. If the syringe has a different calibration, use its units-per-milliliter value rather than assuming 100. The Insulin syringe unit visualizer is useful for checking how a calculated volume sits against the actual graduations.
Dimensional analysis catches unit errors
Write the units through every line rather than cancelling them mentally:
0.5 mg × 1 mL ÷ 2.5 mg = 0.2 mL
The mg units cancel, leaving mL. For a U-100 syringe:
0.2 mL × 100 U ÷ 1 mL = 20 U
The mL units cancel, leaving syringe units. If the result still carries mg, mcg, or an unexplained unit label, the calculation is not finished.
This method also exposes a common error: multiplying by concentration when the desired quantity is volume. To find volume, divide mass by mass-per-volume. To find mass from a measured volume, multiply volume by concentration. Reversing those operations can produce a plausible-looking number with the wrong dimensions.
Reconstitution volume changes the answer
Suppose the same 5 mg vial is made to a final volume of 1 mL instead of 2 mL. The concentration becomes 5 mg/mL. A documented amount of 0.5 mg then requires:
0.5 mg ÷ 5 mg/mL = 0.1 mL
On a U-100 syringe, that is 10 units. The prescribed mass stayed at 0.5 mg; the syringe reading fell from 20 units to 10 because the solution became twice as concentrated.
“Add 2 mL” also needs careful reading. The arithmetic uses final liquid volume, not always the nominal volume of diluent pushed into a vial. Powder displacement, vial geometry, transfer technique, and liquid remaining in a transfer device can make the final volume differ from the volume marked on a syringe. Use the concentration supplied by a legitimate pharmacy or validated product instructions when one exists. If the actual final volume is unknown, the calculated units are unknown.
The Bacteriostatic water calculator — how much to add can help with volume arithmetic, but it cannot validate the product, sterility, compatibility, or beyond-use date. Bacteriostatic water is not a universal fix for an unlabeled or unsuitable powder.
A second calculation is a useful check
After calculating the syringe reading, calculate the mass back from that reading:
Mass = syringe units ÷ syringe units per mL × concentration
For the 20-unit example:
20 U ÷ 100 U/mL × 2.5 mg/mL = 0.5 mg
The result matches the documented amount. If the reverse calculation produces 0.0005 mg or 5 mg instead, check whether mg and mcg were mixed or whether the wrong syringe scale was used.
Building the calendar without inventing a protocol
A calendar is straightforward once the treatment instructions are explicit. The first date is the anchor. Each planned interval advances the date by the stated number of days or by the stated calendar rule. The next amount is then entered from the documented step, not generated from a generic internet schedule.
For a fixed step size, the arithmetic may look like this:
Next planned amount = current documented amount + documented step size
For a schedule with individually specified steps, use each next amount as written instead. Do not assume that a step size remains constant if the treatment instruction lists a different sequence.
A calendar should distinguish planned from actual. Planned date means when the next administration was intended to occur. Actual date means when it happened. If an administration was delayed, held, changed, or omitted, preserve the original plan and add the actual event rather than silently rewriting history.
A dated record should also preserve the concentration used on that date. If a person changes from 5 mg in 2 mL to 5 mg in 1 mL, the same syringe marking no longer represents the same mass. A date without a vial concentration can be insufficient for reconstructing exposure.
This is where a GLP-1 dose calendar becomes more than a row of reminders. The record tells the treatment team what exposure actually occurred. A person who took a step late, held for symptoms, or used a different vial concentration has a different treatment history from someone who followed the original dates exactly.
Dosyne’s log can record the vial and administration details that make the later conversation less dependent on memory. The useful record is unglamorous: date, documented amount, calculated volume or units, actual amount taken, concentration, vial identifier, site, and any relevant symptom or interruption.
Holds, delays, and missed administrations
A hold is a clinical change to the plan. A delay may be a logistical event, a symptom-driven pause, or a missed administration. The label matters because the next decision depends on why the calendar changed.
Do not make up a replacement interval by compressing later dates. Do not use a larger syringe reading to catch up. Missed-dose instructions vary by compound and formulation, and the correct response may depend on how much time has passed and how the person feels. The licensed prescriber or pharmacist should supply that decision; the log should preserve the facts.
Record the reason without turning it into a diagnosis. “Administration delayed because of vomiting” is a factual event. “The dose was too strong” is an interpretation that may not be established by the record.
Semaglutide titration schedule and tirzepatide dose escalation
Search results sometimes present a semaglutide titration schedule as though one table fits every person. It does not. Semaglutide products and uses can have different labeled instructions, and compounded or research preparations introduce additional uncertainty about concentration and handling. A planner can map the schedule already supplied for a specific person; it should not generate one from a search query.
The same applies to tirzepatide dose escalation. A sequence copied from one product label, clinic handout, or social post may not apply to another formulation or indication. The mechanical question is narrower: given a documented mass and a verified concentration, what volume and syringe marking represent that mass?
For mass-to-volume work that begins in micrograms, use the mcg to units converter for an insulin syringe, then check the result against the vial concentration and syringe calibration. Independent arithmetic checks are sensible when the consequence of a misplaced decimal is a real injection.
Neither semaglutide nor tirzepatide should be treated as interchangeable merely because both involve GLP-1 signaling. Their pharmacology, approved formulations, labeling, and clinical instructions are not identical. A calendar can display either sequence; it cannot collapse those differences.
A product label and a research-vial label also answer different questions. Approved labeling may specify a formulation, route, storage conditions, and instructions for a particular use. A “research use only” label does not establish that the material is suitable for injection, that the stated concentration is accurate, or that the contents are sterile. The same conversion formula applies to numbers, but the reliability of those numbers may not be comparable.
Syringe graduations and practical measurement limits
A computed value is not automatically a measurable value. If the arithmetic produces 7.3 units but the syringe markings are separated by 1 or 2 units, the visible reading may require an approximation. That approximation should not be hidden by rounding the displayed result to a false level of precision.
Read the barrel at the leading edge of the plunger, keep the syringe scale visible, and use the smallest graduation the device actually supports. Avoid transferring a volume between syringes by assuming their markings match. U-100 refers to calibration, not a guarantee that every barrel has identical graduations or readability.
Air bubbles alter the delivered volume and make a small measurement harder to interpret. A syringe reading also cannot repair a concentration error. If the vial label, final volume, syringe scale, or documented amount is unclear, stop the calculation and resolve the ambiguity before relying on the result.
A 0.01 mL difference represents 1 unit on a U-100 scale. At 2.5 mg/mL, that difference represents 0.025 mg. At 25 mg/mL, it represents 0.25 mg. The same visual measurement difference therefore has a different mass consequence at a different concentration. This is one reason concentration belongs beside every recorded syringe reading.
Do not report more precision than the inputs support. If the vial amount is approximate, the final volume was not measured, or the syringe graduations cannot resolve the calculated value, a result such as 7.26 units creates false confidence. Preserve the unrounded calculation for review, then resolve the measurement limitation through the dispensing instructions or treatment team.
Storage, sterility, and what the calculation cannot know
Stability is a separate question from arithmetic. A solution may calculate correctly and still be degraded, contaminated, incorrectly stored, or outside a validated beyond-use period.
Follow the storage and beyond-use instructions from the licensed pharmacy or approved product labeling when those instructions exist. Temperature excursions, light exposure, repeated vial entry, agitation, container material, pH, preservative content, and the particular peptide can all matter. Do not infer a stability period from the appearance of the liquid. A clear solution is not proof of potency or sterility.
For research material, the uncertainty is larger. Most research peptides are not approved by the FDA or EMA for human use. Material sold as “research use only” is not manufactured to pharmaceutical standards, and purity, sterility, identity, concentration, and actual content are not guaranteed. Reconstituting it with bacteriostatic water does not turn it into a validated injectable medicine.
The vial’s stated amount may refer to a nominal quantity rather than a verified assay result. A calculator must use the stated quantity because it has no access to laboratory testing. If the actual content differs from the label, every downstream volume and unit calculation differs too.
Avoid treating a calculator output as a quality certificate. It verifies a relationship between the numbers supplied; it does not verify the vial’s contents. The Peptide reconstitution calculator that shows its working is therefore most useful when the input concentration and final volume come from reliable, documented instructions.
Do not infer sterility from a sealed appearance, clarity, lack of particles, or refrigeration. Do not infer stability from a date copied from a different peptide or solvent. Validated stability data must apply to the specific molecule, concentration, container, storage condition, and handling process.
Severe or persistent vomiting, inability to keep fluids down, severe abdominal pain, fainting, confusion, signs of an allergic reaction, or other acute symptoms warrant prompt medical attention. The calendar is not an emergency tool.
A record that helps the next treatment decision
A dose log is not merely a compliance diary. It is evidence about exposure. Without dates, the treatment team may have to reconstruct whether a symptom followed an increase, whether an administration was delayed, whether two vials had different concentrations, or whether the planned interval was actually observed.
Record the compound name, vial amount, final volume, calculated concentration, documented amount, calculated volume, syringe units, planned date, actual date, vial identifier or preparation date, and injection site. Add relevant symptoms without trying to convert the symptom log into a diagnosis. “Vomited twice overnight” is more useful than “felt bad.”
If the amount was recorded in micrograms, retain the original microgram value as well as the converted milligram value. If the preparation was changed, record the old and new concentrations on separate lines. Never overwrite the previous concentration, because doing so can make older unit readings appear to represent the new preparation.
A site map can help prevent repeatedly using the same area, but it does not replace instructions about injection technique or site suitability. The same principle applies to reminders: a reminder can mark the calendar, not authorize an administration.
If a new vial has a different strength or reconstitution volume, recalculate from the beginning. Carrying forward last month’s unit mark is unsafe bookkeeping. Dosyne’s local-first design keeps the calculation and log on the device, with no account or server required; that privacy feature does not remove the need to verify the underlying numbers.
A pre-calculation checklist
Before accepting a conversion, confirm each item:
- The compound name is recorded exactly as supplied.
- The vial amount is identified in mg or mcg.
- The final liquid volume is known in mL.
- The concentration is calculated from those matching units.
- The documented amount uses the same mass unit as the concentration.
- The syringe calibration is confirmed, such as U-100.
- The calculated volume fits the syringe’s capacity and graduations.
- The vial identifier or preparation date is attached to the result.
- Storage and beyond-use information comes from applicable validated instructions.
- Any uncertainty is left visible rather than replaced with an estimate.
This checklist is deliberately mechanical. It does not decide which compound, amount, interval, or escalation is appropriate. It reduces the chance that a clinical instruction will be miscopied during conversion.
Bottom line
Use a GLP-1 titration schedule planner as a transcription and arithmetic instrument: take the documented starting amount, step, interval, and first date; calculate concentration; convert each documented amount to volume and syringe units; check the result by converting it back to mass; then record what actually happened. Do not use it to invent escalation, repair a missed administration, or certify an unverified research peptide. If the vial concentration, syringe calibration, final volume, or treatment instruction is uncertain, the correct result is not a clever estimate. It is an unresolved question for the licensed prescriber or pharmacist.
For the local iPhone and Android tool, search for “Dosyne Peptide Calc & Tracker” in the App Store or Google Play.
The same arithmetic, in your pocket
Dosyne keeps the concentration attached to every logged dose, so a history stays readable months later even after the vial changes. Free on iPhone and Android, with no account and no server.
Frequently asked questions
What is a GLP-1 titration schedule?
A GLP-1 titration schedule is a licensed prescriber-defined plan for changing an amount over time. It specifies the starting amount, the size of each step, and the minimum interval between steps. A planner can place those instructions on dates and convert each prescribed amount into syringe units. It does not determine whether escalation is appropriate or replace a licensed prescriber’s decision.
How long should you stay at each GLP-1 dose?
The interval is set by the licensed prescriber and by tolerance, not by a generic calendar. Gastrointestinal effects can persist after receptor effects are apparent, so the treatment team may keep an amount unchanged, extend the interval, or step back. A calendar can show the planned interval, but it cannot assess symptoms, hydration, other medicines, or the reason to change course.
What is a semaglutide titration schedule?
A semaglutide titration schedule is the individualized sequence of prescribed amounts and intervals used to adjust semaglutide. Different products, indications, formulations, and patients can have different instructions. The safe calculation is mechanical: convert the prescribed mass to volume using the actual concentration, then convert volume to syringe units. Do not treat an online example as a semaglutide dosing protocol; a licensed prescriber must establish the instructions.
What does tirzepatide dose escalation mean?
Tirzepatide dose escalation means moving from one licensed prescriber-selected amount to another after an interval chosen for that patient. The phrase describes a clinical decision, not a universal timetable. A planner can record the intended step and calculate its syringe reading when a compounded or reconstituted concentration is known. It cannot decide whether the next step is safe.
How do I convert a peptide dose to insulin-syringe units?
First calculate concentration: total peptide amount divided by final liquid volume. Then calculate injection volume: prescribed amount divided by concentration. For a U-100 insulin syringe, multiply milliliters by 100 to get syringe units. For example, 5 mg in 2 mL is 2.5 mg/mL; a prescribed 0.5 mg is 0.2 mL, or 20 U on a U-100 syringe. The calculation only works when the vial amount, final volume, mass units, and syringe calibration are known.
What should I do if I miss a GLP-1 dose?
A missed dose does not have one universal correction. The answer depends on the compound, formulation, time elapsed, prior amount, symptoms, and the instructions supplied with the prescribed product. Do not compress the calendar or double a later syringe reading to compensate. Contact the prescribing professional or pharmacist for the specific missed-dose instruction, then record what happened.
What is a hold in GLP-1 titration?
A hold means keeping the current prescribed amount unchanged rather than taking the next planned step. The treatment team may extend an interval when gastrointestinal tolerance is poor, intake or hydration is affected, or the current amount is sufficient for the treatment plan. A hold is not a failed schedule; it is a deliberate change that should be dated and recorded.
Are research peptides safe to reconstitute and inject?
Most research peptides are not approved by the FDA or EMA for human use. Material sold as research use only is not manufactured to pharmaceutical standards, and purity, sterility, identity, concentration, and actual content are not guaranteed. Reconstitution can introduce contamination or concentration errors. A clean calculation cannot make an unverified product sterile, accurately labeled, or suitable for injection.
How long is reconstituted peptide stable?
There is no single stability period for every peptide, solvent, concentration, container, and storage condition. Stability depends on the molecule, pH, temperature, light, agitation, preservatives, container, and validated manufacturer data. Follow the product’s legitimate labeling or the dispensing pharmacy’s instructions. For research material without validated data, the true beyond-use period is unknown; refrigeration alone does not establish stability.